Poolbeg Pharma plc – POLB 001 Data to be Presented at American Society of Hematology Annual Meeting

Potential to address cancer treatment related Cytokine Release Syndrome

3 November 2023  Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that an abstract detailing POLB 001’s promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for presentation at 65th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, to be held 9-12 December 2023 in San Diego, California.

Read more…